Hutchmed (China) Limited Appointment of Non--Executive Director (6322L)
16 Mai 2022 - 1:00PM
UK Regulatory
TIDMHCM
RNS Number : 6322L
Hutchmed (China) Limited
16 May 2022
Appointment of Non-Executive Director
Hong Kong, Shanghai & Florham Park, NJ - Monday, May 16,
2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM;
HKEX:13) announces that Mr Lefei Sun has been appointed as a
Non-Executive Director with effect from May 16, 2022 and he will
hold office until the next annual general meeting ("AGM") of
HUTCHMED when he will stand for re-election.
The Board of HUTCHMED considers that the appointment of Mr Sun
will provide significant benefits to HUTCHMED in view of his
experience in capital markets, M&A and business strategy. Aged
42, Mr Sun has been the Managing Director and Head of China
Healthcare for General Atlantic since 2018, in charge of private
equity investment and portfolio management in the healthcare and
life sciences sectors. General Atlantic owns approximately 3% of
the ordinary shares of HUTCHMED, through its affiliate General
Atlantic Singapore HCM Pte. Ltd.
Mr Simon To, Chairman of HUTCHMED, said, "On behalf of the
Board, I would like to extend a warm welcome to Mr Sun. I believe
his appointment will further strengthen our Board and we look
forward to leveraging the wealth of experience that he brings to
the table from his career in life sciences and healthcare
investment."
Before joining General Atlantic, Mr Sun was the Founding Partner
of Huatai Healthcare Investment Fund, successfully leading the
investment in Mindray Medical, which is listed on Shenzhen Stock
Exchange (SZSE:300760). Prior to that, Mr Sun held various
investment roles at Credit Suisse and OrbiMed, and a strategy
consultant role at McKinsey & Company, all in the healthcare
sector. Mr Sun holds a Bachelor of Science degree in Mathematics
and Physics from Tsinghua University. He also holds a Master of
Arts degree in neuroscience from the Johns Hopkins University.
Mr Sun also has relevant Board experience with both publicly
listed and private companies, having held the following
directorships in the past five years:
Current Directorships: Previous Directorships in the last five years:
Adagene Inc. (Nasdaq:ADAG) Biotheus Inc.
Adagene (Hong Kong) Limited CANbridge Pharmaceuticals Inc. (HKEX:1228)
Adagene (Suzhou) Ltd Huatai Healthcare Investment Fund
Genesis MedTech Group Inc. Ocumension Therapeutics Inc. (HKEX:1477)
Hong Kong Asia Medical Holding Limited
Under the terms of the appointment of Mr Sun as a non-executive
director of the Company until the next AGM, he has agreed that he
will not receive any fee for his service and that his appointment
will be renewed for successive 12-month periods, unless he is not
re-elected at the next AGM or his appointment is otherwise
terminated earlier by either party in writing.
Appointment Regulatory Disclosures
Save for the appointments listed above, Mr Sun has held no other
directorships during the period of five years prior to his
appointment as a director of HUTCHMED. Save for his role with
General Atlantic, Mr Sun does not have any relationship with any
Directors, senior management or substantial or controlling
shareholders of HUTCHMED. Mr Sun does not have any interest in the
ordinary shares of HUTCHMED within the meaning of Part XV of the
Securities and Futures Ordinance (Cap.571 of the Laws of Hong
Kong).
Save for the information disclosed above, there is no other
information in relation to Mr Sun that is required to be disclosed
pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies or Rule 13.51(2) of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and there are
no other matters concerning the appointment of Mr Sun that are
required to be brought to the attention of the shareholders of
HUTCHMED.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharma-ceutical company. It is committed to
the discovery and global develop-ment and commercial-ization of
targeted therapies and immuno-therapies for the treatment of cancer
and immuno-logical diseases. It has more than 4,600 personnel
across all its companies, at the center of which is a team of about
1,700 in oncology/immunology. Since inception it has advanced 12
cancer drug candidates from in-house discovery into clinical
studies around the world, with its first three oncology drugs now
approved and marketed in China. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 97 83 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBQLFFLELEBBF
(END) Dow Jones Newswires
May 16, 2022 07:00 ET (11:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
